placebo (saline) + Olipudase alfa
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sphingomyelin Lipidosis
Conditions
Sphingomyelin Lipidosis
Trial Timeline
Dec 18, 2015 → Oct 19, 2023
NCT ID
NCT02004691About placebo (saline) + Olipudase alfa
placebo (saline) + Olipudase alfa is a phase 2/3 stage product being developed by Sanofi for Sphingomyelin Lipidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02004691. Target conditions include Sphingomyelin Lipidosis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02004691 | Phase 2/3 | Completed |
Competing Products
6 competing products in Sphingomyelin Lipidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Recombinant human acid sphingomyelinase | Sanofi | Phase 1 | 32 |
| Olipudase alfa | Sanofi | Pre-clinical | 22 |
| GZ402665 | Sanofi | Phase 2 | 51 |
| Olipudase alfa | Sanofi | Phase 1/2 | 40 |
| olipudase alfa (GZ402665) | Sanofi | Pre-clinical | 22 |
| rhASM + rhASM + rhASM + rhASM + rhASM | Sanofi | Phase 1 | 32 |